Cure My Disease

Don't miss your cure!

 Log in / Sign up

3D MRI scan may predict liver cancer treatment success

NCT ID NCT07716345

Not yet recruiting Knowledge-focused Sponsor: Second Affiliated Hospital of Xi'an Jiaotong University Source: ClinicalTrials.gov ↗

First seen Jul 21, 2026 · Last updated Jul 22, 2026 · Updated 1 time

Summary

This study investigates whether a specialized MRI scan called three-dimensional magnetic resonance elastography (3D-MRE) can predict how well patients with initially unresectable liver cancer will respond to conversion therapy. The scan measures the stiffness and other physical properties of tumors, which may vary between patients and correlate with treatment outcomes. Researchers will enroll 100 adults with liver cancer who are scheduled for conversion therapy and compare their baseline scan results with their actual response to treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Three-Dimensional Magnetic Resonance Elastography (3D-MRE) scan
What this could lead to
If successful, this could give doctors a way to identify which patients with initially unresectable liver cancer are most likely to benefit from conversion therapy, potentially improving surgical outcomes.
What could go wrong
This is an early-stage observational study with only 100 participants, so results may not apply to all patients. The scan's ability to predict response needs to be confirmed in larger trials.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATO CELLULAR CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cholangiocarcinoma hepatocellular carcinoma intrahepatic cholangiocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEPATO CELLULAR CARCINOMA INTRAHEPATIC BILE DUCT CARCINOMA METASTATIC HEPATOCELLULAR CARCINOMA

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.